India has taken a significant step in cancer care with the introduction of a seven-minute injection for lung cancer patients. The treatment, called Tecentriq, has been launched by Roche in India and is designed to make immunotherapy faster, simpler, and more patient friendly. The drug is intended for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer in the country. Unlike traditional intravenous immunotherapy that can take several hours in hospitals, this new option is administered as a subcutaneous injection that takes only about seven minutes.
Faster Treatment and Greater Patient Comfort
Doctors say the biggest advantage of the new method is convenience. Patients no longer need to spend long hours connected to IV drips in hospitals. Instead, the injection is given under the skin, usually in the thigh, allowing the process to be completed quickly. This shift is expected to reduce hospital congestion, shorten waiting times, and make treatment less physically and mentally exhausting for patients. Medical experts also believe it may improve treatment adherence, especially for elderly patients or those travelling long distances for care.
How the Drug Works
The treatment uses atezolizumab, an immunotherapy drug that blocks a protein known as PD-L1. Cancer cells use this protein to evade the immune system. Once it is blocked, the body’s immune system can better identify and attack cancer cells. Doctors note that patients with higher PD-L1 levels in their tumours are more likely to benefit from this therapy. The drug may be used alone or in combination with other treatments depending on the stage of cancer and the patient’s condition.
Who Can Benefit
The injection is primarily meant for patients with non-small cell lung cancer, which accounts for the majority of lung cancer cases in India. Experts estimate that nearly half of NSCLC patients could be eligible for this form of immunotherapy, depending on their biomarker profile. Clinical results suggest improved survival outcomes and slower disease progression in suitable patients, making it a promising addition to existing cancer treatment options.
High Cost Remains a Major Concern
Despite its medical benefits, the treatment has raised concerns over affordability. Each dose costs around ₹3.7 lakh, and most patients require multiple doses, pushing total treatment costs into several lakhs. Specialists say immunotherapy is expensive due to advanced research, complex development processes, and high manufacturing costs. In India, such treatments typically range between ₹1.5 lakh and ₹4 lakh per cycle.
To ease financial pressure, Roche has introduced a patient support programme called Blue Tree. The drug is also covered under the Central Government Health Scheme (CGHS), which may help eligible patients access reimbursement support. However, experts say broader policy support is still needed to make advanced cancer care widely affordable.
A Step Forward in Cancer Care
Despite cost challenges, doctors view the seven-minute injection as an important shift in cancer treatment. The shorter procedure time, reduced hospital dependence, and improved patient comfort represent a meaningful upgrade in how immunotherapy is delivered in India, offering hope for better quality of life for lung cancer patients.
